JADE101
Phase 2Small molecule
JADE101 is one of 59 small molecule programs targeting IgA Nephropathy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
59 competitors in Phase 1
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 2
Fludara
SanofiPhase 2
Venclexta
AbbViePhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Erbitux
IImclone
Phase 2
Rayos
RRoxane Laboratories
Phase 2
Navitoclax
AbbViePhase 2
Yervoy
Bristol-Myers SquibbPhase 1
Benznidazole
CCorestemchemon, Inc.
Phase 1
VX-407
Vertex PharmaceuticalsPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JADE101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJade Biosciences, Inc.